National Comprehensive Cancer Network

About NCCN

NCCN to Host First Annual Hematologic Malignancies Congress in NYC

Internationally known faculty to share advances in the treatment of blood cancers.

JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) will debut a new educational program on September 8: the 1st Annual NCCN Hematologic Malignancies Congress. The event will be held at the Crown Plaza Times Square in New York.

Over 100,000 new cases of hematologic malignancies will be diagnosed in 2006 alone. Important new treatment advances for these diseases have been introduced recently, improving the care available to patients with these blood cancers. As a result, the NCCN is hosting this full-day meeting featuring world-renowned experts who will discuss these clinical advances. These including the integration of the recently FDA approved dasatinib (Sprycel, Bristol-Myers Squibb) in the treatment of chronic myelogenous leukemia and new agents such as lenalidomide (Revlimid, Celgene) in the treatment of multiple myeloma and myelodysplastic syndromes. These changes are all reflected in the NCCN Clinical Practice Guidelines in Oncology,™ the recognized standard for clinical policy in the oncology community. These guidelines are updated continually in a consensus-driven process with explicit review of the evidence by multidisciplinary panels of expert physicians from NCCN member institutions.

Leaders of these multidisciplinary panels will present important updates to the NCCN guidelines outlining treatment advances, and include Andrew D. Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center and Margaret R. O’Donnell, MD, City of Hope Cancer Center.

There will be a media briefing at 11:30 AM, during the meeting, to discuss the NCCN Clinical Practice Guidelines on hematologic malignancies. Several thought leaders from NCCN institutions will focus on the advances that have been made in treating blood cancers and the options that are now available for patients coping with these diseases. Response to the program has been outstanding. The second annual Congress is already planned to be a 2-day event to be held in September, 2007.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit

The NCCN Member Institutions are:

  • Fred & Pamela Buffett Cancer Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • City of Hope Comprehensive Cancer Center
  • Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • Roswell Park Cancer Institute
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • University of Alabama at Birmingham Comprehensive Cancer Center
  • UC San Diego Moores Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Comprehensive Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital